FDA Accepts Alvotech's Resubmitted Biologics License Application (BLA) For AVT02, A High-Concentration Interchangeable Biosimilar Candidate To Humira
Portfolio Pulse from Benzinga Newsdesk
The FDA has accepted Alvotech's resubmitted Biologics License Application (BLA) for AVT02, a high-concentration interchangeable biosimilar candidate to Humira. This could potentially impact the market share of Humira, which is produced by AbbVie Inc.
September 20, 2023 | 8:33 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The FDA's acceptance of Alvotech's BLA for AVT02 could potentially impact the market share of Humira, which is produced by AbbVie Inc.
The FDA's acceptance of Alvotech's BLA for AVT02, a biosimilar candidate to Humira, could potentially lead to increased competition for Humira, which is produced by AbbVie Inc. This could negatively impact AbbVie's market share and revenues from Humira sales.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100